drugset
drugset / Trial / NCT02070523

Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:

NCT02070523 ↗

Phase 3 Unknown 200 enrolled Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine, compared with Daunorubicin(DNR), whether Pegylated liposomal doxorubicin (PLD) inducing higher complete remission (CR) rate, in untreated primary ALL adult patients with VDCLD regimen induction therapy. Second, to determine, compared with the DNR, whether chemotherapy containing PLD with a higher response rates and greater safety in adult ALL

Timeline

Start
2013-12
Primary completion
2015-11
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Daunorubicin Small molecule 45 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 36 mg/m2 Intravenous
Background CTX Unknown 800 mg/m2 Intravenous
Background Dex Unknown 10 mg Intravenous
Background L-asp Unknown 6000 unknown Intravenous
Background VCR Unknown 1.4 mg/m2 Intravenous

Indications

acute lymphoblastic leukemia